1 in 60 Women in general gynaecology practice have lichen sclerosus — and prevalence is likely higher due to misdiagnosis and asymptomatic cases
15–40% of lichen sclerosus cases are asymptomatic — meaning the condition can progress without obvious symptoms being noticed
4–7% Lifetime risk of vulvar squamous cell carcinoma in untreated lichen sclerosus — reduced substantially with consistent treatment and monitoring

What lichen sclerosus actually is

Lichen sclerosus is a chronic inflammatory skin condition that primarily affects the vulva in women, though it can also appear on other body areas. The skin becomes thin, white, and fragile — often described as having the appearance of cigarette paper. It can cause intense itching, discomfort, pain during sex, and over time, structural changes including scarring and narrowing of the vaginal opening.

The exact cause isn't fully established. Current understanding points to an autoimmune mechanism: the immune system attacks the skin of the vulva, leading to chronic inflammation and tissue damage. There's also a hormonal dimension — the condition is more prevalent at times of lower oestrogen (prepuberty and postmenopause), and oestrogen appears to have a protective effect on vulvar skin integrity.

It's not infectious. It can't be passed to a partner. And it's not caused by poor hygiene — in fact, overwashing and scented products aggravate it.

Why it takes so long to diagnose

The itching that characterises lichen sclerosus is frequently attributed to thrush. Women buy over-the-counter antifungal treatment, which may temporarily reduce irritation without treating the underlying condition. The diagnostic delay is well documented: studies have found average time from symptom onset to correct diagnosis of several years in some populations.

There are other reasons for the gap. Some women feel embarrassed discussing vulvar symptoms. Some GPs have limited familiarity with the condition. And in postmenopausal women, symptoms are often attributed to GSM (genitourinary syndrome of menopause) — which is a real and separate condition, but which coexists with lichen sclerosus in some women, making distinction harder without examination.

Practical tip

If you have persistent vulvar itching that doesn't resolve with antifungal treatment, or skin that looks white or pale in the vulvar area, ask specifically for a vulvar examination. You're entitled to say: "I'd like a proper look to rule out lichen sclerosus." A diagnosis typically involves visual examination and, if uncertain, a small biopsy under local anaesthetic.

Treatment: what to expect

The 2024 EuroGuiderm guidelines confirm what dermatologists and gynaecologists have known for decades: high-potency topical corticosteroids are first-line treatment. Clobetasol propionate 0.05% ointment is the standard. When used correctly — typically as a reducing course over several months, then maintenance — it controls symptoms in the majority of women and prevents structural progression.

Research note

A 2024 prospective observational study evaluated fractional CO2 laser therapy in 75 women with refractory lichen sclerosus over four treatment sessions. Significant reductions in itch, pain, and dyspareunia were observed. Laser is now considered a reasonable second-line option for women who don't achieve adequate symptom control with steroid-based treatment.

Tacrolimus 0.1% (a topical calcineurin inhibitor) is an alternative for women who don't tolerate steroids or who need long-term maintenance without the skin-thinning risk of steroids, though it comes with its own considerations. A dermatologist or specialist gynaecologist is the right person to guide long-term management.

The thing most women aren't told: treatment is ongoing. Lichen sclerosus doesn't resolve with a single course of treatment. Annual review is recommended to monitor for symptom control and to screen for any atypical changes in the skin — given the small but real cancer risk, this is not optional maintenance.

🩺

When to seek urgent review

See a doctor promptly if: symptoms don't respond to treatment; you notice a new lesion, thickened skin, or ulceration in the vulvar area; or you have bleeding or pain not explained by treatment side effects. Any persistent skin change in the context of lichen sclerosus should be assessed to rule out malignant transformation.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.

References

  1. Kirtschig G, et al. EuroGuiderm guideline on lichen sclerosus — treatment. Journal of the European Academy of Dermatology and Venereology. 2024. PubMed
  2. Bleeker MCG, et al. Lichen sclerosus among women in the United States. BJU International. 2020. PMC
  3. Efficacy of Fractional CO2 Laser in Refractory Vulvar Lichen Sclerosus. Life (Basel). 2024;14(12):1678. Link